|Bid||127.71 x 200|
|Ask||128.04 x 100|
|Day's Range||130.66 - 133.45|
|52 Week Range||119.25 - 148.32|
|PE Ratio (TTM)||278.45|
|Earnings Date||Apr 17, 2018|
|Forward Dividend & Yield||3.36 (2.52%)|
|1y Target Est||150.86|
NEW BRUNSWICK, N.J. , Feb. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13 , at The Boston Marriott Copley Place, ...
Law Offices of Howard G. Smith continues its investigation on behalf of Johnson & Johnson Investors investors concerning the Company and its officers’ possible violations of federal securities laws.
NEW YORK, Feb. 20, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Johnson & Johnson between February ...
NEW YORK, Feb. 20, 2018-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Johnson & Johnson and certain of its officers, ...
BSX Stock Recovers after a Robust 4Q17: What's to Come? In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform, with most US healthcare companies reporting one-time financial effects on their balance sheets.
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
Something odd has been happening to short-term bank bonds. So far this month, spreads on banks' two-year bonds have widened by more than 15 basis points, according to Bank of America Merrill Lynch. For ...
Johnson & Johnson is seeking buyers for its sterilization products division, people familiar with the matter said, as the health-care conglomerate continues to sell off non-core assets.
Novartis: What Are the Major Growth Drivers for 2018? On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the patients with ankylosing spondylitis. According to the Arthritis Foundation, “Spondyloarthritis is an umbrella term for inflammatory diseases that involve both the joints and the entheses (the sites where the ligaments and tendons attach to the bones).
If there were a healthcare Olympics, this company would bring home the gold this year because of its rock-solid financials.
NEW YORK (AP) — Stocks closed out their strongest week in five years Friday and have now recovered more than half of the losses they suffered in a plunge at the beginning of the month.
Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.
Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.
The Klein Law Firm announces the commencement of an investigation of Johnson & Johnson concerning possible violations of federal securities laws.
Novartis: What Are the Major Growth Drivers for 2018? On September 7, 2017, Novartis (NVS) announced positive results from its pivotal Phase 2 study, which highlighted the consistent efficacy demonstrated by Aimovig. This efficacy was measured through changes in monthly migraine days in chronic migraine patients who failed to respond to previous preventive therapies.
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
SKILLMAN, N.J. , Feb. 16, 2018 /PRNewswire/ -- Reinforcing leadership in scientifically-driven skincare, Johnson & Johnson Consumer Inc. will present eight Scientific Posters at this year's American Academy ...